Posted by Michael Wonder on 09 Jun 2022
Lupin receives tentative approval from U.S. FDA for ivacaftor tablets
8 June 2022 - Lupin today announced that it has received tentative approval from the United States FDA for its abbreviated new drug application ivacaftor 150 mg tablets to market a generic equivalent of Kalydeco 150 mg tablets of Vertex Pharmaceuticals.
This product will be manufactured at Lupin’s Nagpur facility in India.
